盐酸苯海索治疗帕金森病与帕金森综合征效果分析

Effect of Trihexyphenidyl Hydrochloride on Parkinson 's Disease and Parkinson's Syndrome

目的研究盐酸苯海索对于帕金森病与帕金森综合征的治疗效果。方法方便选取2015年4月—2017年4月该院收治的30例帕金森病患者与30例帕金森综合征患者作为研究对象,所有患者均采用盐酸苯海索进行治疗,1次/d,2 mg/次,持续治疗14 d,分析所有患者经治疗后的临床疗效和不良反应发生情况。结果经治疗后,30例帕金森病患者的治疗有效率为66.67%(20例),帕金森综合征患者的治疗有效率为53.33%(16例),帕金森病的治疗有效率高于帕金森综合征(P<0.05);经治疗后,两组患者均出现嗜睡、恶心、口干和头晕的不良反应,帕金森病患者不良反应的发生率为26.67%(8例),帕金森综合征患者不良反应的发生率为40.00%(12例),帕金森病患者不良反应的发生率低于帕经森综合征患者(P<0.05)。结论盐酸苯海索对于帕金森病与帕金森综合征都具有较为明显的治疗效果,能够帮助缓解病症的临床症状,但总体而言,其对于帕金森病的治疗效果略高,而且不良反应率明显较低,该药物可在帕金森病和帕金森综合征的治疗中进行推广使用。

Objective This paper tries to study the therapeutic effect of trihexyphenidyl hydrochloride on Parkinson’s disease and Parkinson’s syndrome.Methods 30 patients with Parkinson’s disease and 30 patients with Parkinson’s syndrome treated from April 2015 to April 2017 were convenient selected,all patients were treated with trihexyphenidyl hydrochloride,once a day,2 mg every time,for 14 days,the clinical efficacy and adverse reaction of all patients were analyzed.Results After treatment,the effective rate of treatment for 30 patients with Parkinson’s disease was 66.67%(20 cases),the effective rate was 53.33%(16 cases),and the treatment efficiency was higher than that of Parkinson’s disease(P<0.05).After treatment,the adverse reactions of drowsiness,nausea,thirsty and dizziness were observed in both groups.The incidence of adverse reaction in patients with Parkinson’s disease was 26.67%(8 cases),the incidence of adverse reaction in patients with Parkinson’s syndrome was 40.00%(12 cases),and the incidence of adverse reaction in patients with Parkinson’s disease was lower than that of patients with in multitudes syndrome(P<0.05).Conclusion Trihexyphenidyl is effective in the treatment of Parkinson’s disease and Parkinson’s disease,it can help to alleviate the clinical symptoms,but overall,it has a little effect on the treatment of Parkinson’s disease,and the adverse reaction rate is obviously low,which can be used in the treatment of Parkinson’s disease and Parkinson’s syndrome.